GE HealthCare StarGuide GX Secures CE Mark Approval

GE HealthCare has revealed that its StarGuide GX system has received CE Mark approval, a state-of-the-art digital 4D SPECT/CT aimed at providing precision, efficiency, and flexibility in molecular imaging.The milestone will enable clinicians to broaden research and customize care across an increasing variety of tracers, including alpha emitters, as stated by the global med-tech company.StarGuide GX comes at a pivotal time when the rise of complex illnesses—such as cancer, Alzheimer’s, and heart diseases—fuels the need for precise diagnostics and focused treatments. The system enables healthcare providers to surpass energy-range constraints and acquire tracers with exceptional clarity, providing scalable options to handle increasing patient numbers and more intricate treatment protocols.

Also Read: The Regulatory Journey of Indian Pharma: Navigating the Path Ahead

“Our mission is to advance precision health by delivering technologies that meet the evolving needs of clinicians and patients,” said Jean-Luc Procaccini, President and CEO, Molecular Imaging and Computed Tomography, GE HealthCare.

“As nuclear medicine evolves to meet the demands of precision health, StarGuide GX is designed to help researchers and clinicians stay ahead, offering a whole new range of possibilities with one scanner. This innovation reflects our commitment to purposeful technology – supporting cases across care pathways and the practice of theranostics – to help both expand clinical capabilities and improve outcomes for patients worldwide.”